STAT

OCTOBER 10, 2023

But the   drumbeat of layoffs in 2022   has only grown louder this year. biopharma firms cut about 6,000 jobs in 2022 and 11,000 so far this year. percent to about 114,000 in 2022, compared to nearly 107,000 the year before, according to a  report released Sept. He estimated U.S.

Vaccines 134

Vaccines Generic Medicine Packaging 134

European Pharmaceutical Review

AUGUST 25, 2022

Meanwhile, Sandoz would leverage its strong brand and sustain its leading global position by continuing to invest in the key strategic areas of Biosimilars, Antibiotics and Generic Medicines. strength in technology platforms: Gene Therapy, Cell Therapy, Radioligand Therapy, Targeted Protein Degradation and xRNA.

Generic Medicine 98

Generic Medicine 98

European Pharmaceutical Review

JANUARY 30, 2023

Four new medicines recommended for approval The CHMP recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. Sitagliptin/Metformin hydrochloride Sun (sitagliptin/metformin hydrochloride) for the treatment of type 2 diabetes mellitus.

Generic Medicine 96

Generic Medicine 96

European Pharmaceutical Review

APRIL 3, 2023

The committee adopted positive opinions for three generic medicines: Dabigatran Etexilate Accord (dabigatran etexilate) for the prevention of venous thromboembolic events Lacosamide Adroiq (lacosamide) for epilepsy Sugammadex Adroiq (sugammadex) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Vaccines 98

Vaccines Chemotherapy Generic Medicine 98

pharmaphorum

JANUARY 30, 2023

With the production of generic medicine being concentrated in China and India, the ability to flexibly influence the supply of generic medicine, which most antibiotics are, is relatively limited. Larger questions remain around the way in which to support manufacturers to invest in production capabilities for antibiotics.

Generic Medicine 104

Generic Medicine Packaging FDA Labelling 104

European Pharmaceutical Review

JULY 25, 2023

billion in 2022. The small molecule API market is influenced by several factors, including heightened R&D within the pharmaceutical sector, a growing prevalence of chronic illnesses and rising demand for generic medicines. This is a rise from $162.8 A compound annual growth rate (CAGR) growth of 5.9

Compounding 97

Compounding Generic Medicine 97

European Pharmaceutical Review

FEBRUARY 2, 2023

This is long overdue as the current tender process has been one of the root causes for the decline in Europe’s essential medicines manufacturing due to the sole focus on price, to the exclusion of other factors like quality and sustainability of supply. Is localisation the answer for pharmaceutical supply chain resilience?

Generic Medicine 111

Generic Medicine Packaging Documentation Pharmaceutical Companies 111

pharmaphorum

JANUARY 4, 2023

It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US. The drug was originally developed by CV Therapeutics – bought by Gilead in 2009 – and first launched in the US in 2008.

Generic Medicine 59

Generic Medicine FDA 59

pharmaphorum

SEPTEMBER 26, 2022

Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks. ” Hospira isn’t the only generics company trying to bring a version of regadenoson to the US market.

Generic Medicine 52

Generic Medicine FDA 52

European Pharmaceutical Review

JULY 29, 2024

The treatment is already authorised in the US, Japan, China, South Korea, Hong Kong, and Israel, based on data from the worldwide Phase III Clarity AD study, of which results were published in November 2022. Tuznue (trastuzumab) for breast and gastric cancer.

Generic Medicine 52

Generic Medicine 52

pharmaphorum

MARCH 29, 2022

At the end of last year, Pfizer signed an agreement with The Medicines Patent Pool that allowed for its oral antiviral treatment candidate PF-07321332 to be produced and distributed to low- and middle-income countries.

Vaccines 95

Vaccines Generic Medicine 95

Hospital Pharmacy Europe

AUGUST 13, 2024

In 2022, the Executive Steering Group on Shortages and Safety of Medicinal Products was established to ensure a robust response to medicine supply issues caused by major events or public health emergencies. What’s been done about shortages?

Hospitals 59

Hospitals Generic Medicine Communication 59

Pharmaceutical Technology

FEBRUARY 18, 2023

The company offers generic medicines and biosimilars through Sandoz. The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). over FY2021.

Generic Medicine 40

Generic Medicine Immunization 40

The Checkup by Singlecare

OCTOBER 12, 2023

This is because generic medicines are much less expensive than their brand-name counterparts, even though they work just as well. What are the differences between brand name and generic Abilify? Aripiprazole was approved by the FDA in 2015. Aripiprazole is widely available at pharmacies across the U.S.

Dosage 52

Dosage Labelling FDA Adverse Reactions 52

Pharmaceutical Technology

MAY 3, 2023

In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu. However, that percentage of multiple first generics is not very high—approximately 10.6% from 2001 to 2022.”

FDA 98

FDA Generic Medicine Communication 98

Pharmaceutical Technology

DECEMBER 19, 2022

in 2022 to 1% in 2023 due to the “tightening of monetary and financial conditions”. Koerber-Walker discussed how the Inflation Reduction Act, introduced in 2022 , may benefit biologics companies’ funding plans going into the next year. Certain companies will struggle more than others with accruing investment from venture capital firms.

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceutical Companies Generic Medicine Communication 69